Stay updated with breaking news from Clinical Program Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tiziana Life Sciences Ltd Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 -...
13.11.2023 - Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for ...
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B
RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be...
-- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE to date; 71 of 80 patients enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from... | May 11, 2023